{"id":"comparator-ceftriaxone-sodium","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Diarrhea"},{"rate":"1-2%","effect":"Rash"},{"rate":"1-2%","effect":"Phlebitis at injection site"},{"rate":"1%","effect":"Nausea"},{"rate":"1-3%","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL6067656","moleculeType":"Small molecule","molecularWeight":"1323.22"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftriaxone works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, with particular efficacy against aerobic organisms. The drug is bactericidal and is commonly used for serious infections including meningitis, sepsis, and surgical prophylaxis.","oneSentence":"Ceftriaxone sodium is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:02.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including meningitis, sepsis, and lower respiratory tract infections"},{"name":"Surgical prophylaxis"},{"name":"Gonorrhea and other sexually transmitted infections"}]},"trialDetails":[{"nctId":"NCT07207876","phase":"","title":"Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy","status":"RECRUITING","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2026-02-16","conditions":"Pregnancy","enrollment":110},{"nctId":"NCT06819592","phase":"PHASE3","title":"PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-10-30","conditions":"All-cause Mortality, Quality of Life, Disability, Intellectual","enrollment":3300},{"nctId":"NCT05750966","phase":"NA","title":"Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-07-19","conditions":"Cholangitis","enrollment":440},{"nctId":"NCT04869579","phase":"PHASE2","title":"Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.","status":"UNKNOWN","sponsor":"CHRISTUS Health","startDate":"2021-08-15","conditions":"Covid19","enrollment":100},{"nctId":"NCT03477422","phase":"PHASE3","title":"CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria","status":"COMPLETED","sponsor":"Venus Remedies Limited","startDate":"2014-01-11","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis","enrollment":230},{"nctId":"NCT01723150","phase":"PHASE4","title":"Antibiotics for Klebsiella Liver Abscess Study","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2013-11-05","conditions":"Liver Abscess, Pyogenic","enrollment":152},{"nctId":"NCT01014013","phase":"PHASE3","title":"Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04","conditions":"Urinary Tract Infection","enrollment":271},{"nctId":"NCT01254344","phase":"PHASE3","title":"Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-12","conditions":"Infection, Surgical Site Infection","enrollment":599},{"nctId":"NCT00509106","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-07","conditions":"Bacterial Pneumonia","enrollment":622},{"nctId":"NCT00481702","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-12","conditions":"Intra-abdominal Infection","enrollment":300},{"nctId":"NCT00157898","phase":"PHASE4","title":"A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-01","conditions":"Complicated Intra-abdominal Infection","enrollment":134},{"nctId":"NCT00451386","phase":"PHASE2","title":"Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-01","conditions":"Urinary Tract Infections, Bacterial Pneumonia, Soft Tissue Infections","enrollment":400},{"nctId":"NCT00797108","phase":"PHASE2","title":"A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Pneumonia, Bacterial","enrollment":35},{"nctId":"NCT01645735","phase":"PHASE4","title":"Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-10","conditions":"Infections","enrollment":49},{"nctId":"NCT01669980","phase":"PHASE4","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-10","conditions":"Infections, Pneumonia","enrollment":40},{"nctId":"NCT01530763","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-09","conditions":"Infections, Community Acquired Pneumonia","enrollment":161}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: ceftriaxone sodium","genericName":"Comparator: ceftriaxone sodium","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftriaxone sodium is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including meningitis, sepsis, and lower respiratory tract infections, Surgical prophylaxis, Gonorrhea and other sexually transmitted infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}